Investigational drug · Phase 3
Active Comparator: Morphine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
45
Any phase or sponsor naming "Active Comparator: Morphine"
First trial start
2025
May 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Active Comparator: Morphine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Active Comparator: Morphine" as an intervention, largest first.
- Evaluation of the Efficacy of Sublingual Sufentanil (Prescribed as Rescue Analgesia for Acute Postoperative Pain) on the Quality of Health Recovery After Surgery: a Randomized, Controlled, Multicenter, Open-label Trial Against an Active Comparator (SUBLIME)Pivotal-lookingNot yet recruiting
University Hospital, Strasbourg, FranceAcademic, hospital or other
NCT07624006 · 1,150 participants (planned) · Start Jan 1, 2027 · Primary completion Feb 28, 2030
Drug: Sublingual sufentanil 30 µg (one dose per hour, as needed); Morphine sulfate (10 mg every 4 hours as needed) · For: Postoperative Pain
Sites: Strasbourg, France
- Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00820027 · 776 participants · Start Dec 15, 2008 · Primary completion Dec 13, 2010
Drug: Etoricoxib 90 mg; Etoricoxib 120 mg and 6 more · For: Pain, Postoperative
- A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00694369 · 588 participants · Start Jun 2008 · Primary completion Dec 2008
Drug: Comparator: etoricoxib; Comparator: ibuprofen and 2 more · For: Postoperative Dental Pain
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal SurgeryPivotal-lookingActive, not recruiting
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06890533 · 560 participants (planned) · Start May 14, 2025 · Primary completion Apr 17, 2026
Drug: Experimental: YZJ-4729; Placebo Comparator: Saline and 1 more · For: Pain
Sites: Cangzhou, China; Changde, China; Changsha, China · 49 sites in all
Joseph HazeltonIndustry
NCT02462811 · 552 participants · Start Sep 2014 · Primary completion Jul 2015
Drug: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg); Placebo and 1 more · For: Pain; Nausea; Vomiting
Sites: Philadelphia, Pennsylvania
- Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back PainPivotal-lookingCompleted
Zogenix, Inc.Industry
NCT01081912 · 510 participants · Start Mar 2010 · Primary completion Oct 2011
Drug: Placebo; Hydrocodone bitartrate · For: Back Pain Lower Back Chronic
Sites: Phoenix, Arizona; Jonesboro, Arkansas; Anaheim, California · 51 sites in all
- Oral Analgesic Utilization for CHildhood Musculoskeletal InjuriesPivotal-lookingCompleted
St. Justine's HospitalAcademic, hospital or other
NCT02064894 · 501 participants · Start Jul 8, 2013 · Primary completion Jun 22, 2015
Drug: oral morphine and oral ibuprofen; Oral morphine and 1 more · For: Musculoskeletal Injury
Sites: Edmonton, Canada; Ottawa, Canada; Montreal, Canada
- Safety of Fentanyl TAIFUN TreatmentPivotal-lookingStatus unknown
Akela Pharma, Inc.Industry
NCT00822614 · 500 participants (planned) · Start Dec 2008 · Primary completion Dec 2009
Drug: Fentanyl TAIFUN; Opioid · For: Breakthrough Cancer Pain
Sites: Włocławek, Poland
- NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic CancersPivotal-lookingStatus unknown
Medlab ClinicalIndustry
NCT04808531 · 360 participants (planned) · Start Nov 2023 · Primary completion Feb 2024
Drug: NanaBis™; Oxycodone CR and 3 more · For: Cancer Related Pain
- A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy SurgeryPivotal-lookingCompleted
Zogenix, Inc.Industry
NCT02197156 · 241 participants · Start Aug 2002 · Primary completion Feb 2003
Drug: 10 mg HC-ER; 20 mg HC-ER and 4 more · For: Postoperative Pain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- CT001Phase 31 trial
Cessatech A/S · Pain
- MR-107A-02Phase 31 trial
Viatris Specialty LLC · Acute Pain, Post Operative Pain, Pain
- SRP-001Phase 21 trial
South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain
- YZJ-4729Phase 21 trial
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.